[go: up one dir, main page]

MX2010013790A - Composiciones y metodos para tratar inflamacion de corneas. - Google Patents

Composiciones y metodos para tratar inflamacion de corneas.

Info

Publication number
MX2010013790A
MX2010013790A MX2010013790A MX2010013790A MX2010013790A MX 2010013790 A MX2010013790 A MX 2010013790A MX 2010013790 A MX2010013790 A MX 2010013790A MX 2010013790 A MX2010013790 A MX 2010013790A MX 2010013790 A MX2010013790 A MX 2010013790A
Authority
MX
Mexico
Prior art keywords
compostions
methods
corneal inflammation
treating corneal
treating
Prior art date
Application number
MX2010013790A
Other languages
English (en)
Inventor
Pearlman Eric
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of MX2010013790A publication Critical patent/MX2010013790A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eyeglasses (AREA)

Abstract

Un método para tratar inflamación de corneas en un sujeto incluye administrar al sujeto una cantidad terapéuticameflte efectiva de un antagonista de TLR4.
MX2010013790A 2008-06-13 2009-06-15 Composiciones y metodos para tratar inflamacion de corneas. MX2010013790A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6129108P 2008-06-13 2008-06-13
US10149308P 2008-09-30 2008-09-30
PCT/US2009/047407 WO2009152517A1 (en) 2008-06-13 2009-06-15 Compostions and methods for treating corneal inflammation

Publications (1)

Publication Number Publication Date
MX2010013790A true MX2010013790A (es) 2011-03-21

Family

ID=41417157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010013790A MX2010013790A (es) 2008-06-13 2009-06-15 Composiciones y metodos para tratar inflamacion de corneas.

Country Status (12)

Country Link
US (1) US9006210B2 (es)
EP (1) EP2294419B1 (es)
JP (1) JP5550641B2 (es)
KR (1) KR101359102B1 (es)
CN (1) CN102159950B (es)
AU (1) AU2009257259B2 (es)
BR (1) BRPI0915143A2 (es)
CA (1) CA2727847C (es)
EA (1) EA019437B1 (es)
IL (1) IL209947A (es)
MX (1) MX2010013790A (es)
WO (1) WO2009152517A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101473100B1 (ko) * 2013-05-30 2014-12-15 인제대학교 산학협력단 Ｅｂｖ 감염 인간각막상피세포를 이용한 혈관신생 질환용 세포 모델
US20180333461A1 (en) * 2014-12-08 2018-11-22 The University Of Queensland Methods and compositions for treating or preventing flavivirus infections
US10857197B2 (en) 2014-12-12 2020-12-08 The Feinstein Institutes For Medical Research Treatment of HMGB1-mediated inflammation
KR101745524B1 (ko) * 2015-05-29 2017-06-12 아주대학교산학협력단 신규한 tlr2 길항제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DK1218007T3 (da) * 1999-09-13 2011-11-07 Bridge Pharma Inc Optisk aktive isomerer af ketotifen og terapeutiske aktive metaboliter deraf
US6719929B2 (en) * 2000-02-04 2004-04-13 Novartis Ag Method for modifying a surface
WO2004071465A2 (en) * 2003-02-12 2004-08-26 Eisai Co., Ltd Methods and kits for use in the diagnosis and treatment of endotoxemia
EP1879597A2 (en) * 2005-05-13 2008-01-23 Eisai Co., Ltd. Lipid a analogs for treating oral and gastrointestinal mucositis
US20090149647A1 (en) 2005-08-31 2009-06-11 Eisai R&D Management Co., Ltd. Process for production of lipid a analogue
WO2008006046A1 (en) * 2006-07-06 2008-01-10 Case Western Reserve University Ceramide composition and use thereof in treatment of ocular diseases
US9012410B2 (en) * 2006-12-13 2015-04-21 Case Western Reserve University Method of treating intrauterine inflammation

Also Published As

Publication number Publication date
US20110105426A1 (en) 2011-05-05
CN102159950B (zh) 2014-12-17
AU2009257259A1 (en) 2009-12-17
EA201071350A1 (ru) 2011-08-30
AU2009257259B2 (en) 2013-05-02
IL209947A0 (en) 2011-02-28
KR101359102B1 (ko) 2014-02-05
CA2727847C (en) 2014-08-05
EP2294419A4 (en) 2012-01-25
WO2009152517A1 (en) 2009-12-17
JP2011524371A (ja) 2011-09-01
JP5550641B2 (ja) 2014-07-16
EP2294419B1 (en) 2013-08-14
BRPI0915143A2 (pt) 2017-03-21
KR20110026444A (ko) 2011-03-15
CN102159950A (zh) 2011-08-17
CA2727847A1 (en) 2009-12-17
EA019437B1 (ru) 2014-03-31
US9006210B2 (en) 2015-04-14
IL209947A (en) 2014-07-31
EP2294419A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
MY145769A (en) Method for treating or preventing systemic inflammation
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX342951B (es) Composiciones terapeuticamente activas y su metodo de uso.
IN2015DN00450A (es)
WO2009079451A3 (en) Compositions and methods of promoting wound healing
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
PH12013500543A1 (en) Breast cancer therapeutics
WO2013010034A3 (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
WO2009048778A3 (en) Laminins, derivatives, and compositions including same and method for their therapeutic use
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2014075084A3 (en) Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid
IN2014MN02269A (es)
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2013083826A3 (en) Glp-1 agonists
MX2012007234A (es) Nanocristales de monohidrato de calciprotiol.
WO2010030976A3 (en) Methods and compositions for inhibiting atherosclerosis and vascular inflammation
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
MY161853A (en) Pharmaceutical composition and method for treating hypertension
NZ603331A (en) Therapeutic regimens and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
TW201129361A (en) Methods for treating pain

Legal Events

Date Code Title Description
FG Grant or registration